Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules

  • Andrei I. Chapoval
  • Gefeng Zhu
  • Lieping Chen
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 45)


According to the current view, an efficient T-lymphocyte activation requires not only a specific signal delivered through the engagement of a T-cell receptor (TCR) by antigenic peptide-major histocompatibility complex (MHC), but also signals provided by costimulatory molecules. Accumulating evidence indicate that one of the possible reasons for poor immunogenicity of human tumors underlies in the lack of expression of costimulatory molecules (1). Recent studies reveal that, in many cases, antigens alone, especially weak tumor antigen, are insufficient to stimulate immune responses, that is, they are ignored by immune system unless second accessory signals are provided (2).


Fusion Protein Costimulatory Molecule Mouse IgG2a Costimulatory Receptor Latex Microsphere 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Chen, L., Linsley, P. S., and Hellstrom, K. E. (1993) Costimulation of T cells for tumor immunity. Immunol. Today. 14, 483–486.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen, L. (1998) Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today. 19, 27–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71, 1093–1102.CrossRefPubMedGoogle Scholar
  4. 4.
    Guo, Y., Wu, M., Chen, H., Wang, X., Liu, G., Li, G., et al. (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 263, 518–520.CrossRefPubMedGoogle Scholar
  5. 5.
    Guo, Y. J., Che, X. Y., Shen, F., Xie, T. P., Ma, J., Wang, X. N., et al. (1997) Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nature Med. 3, 451–455.CrossRefPubMedGoogle Scholar
  6. 6.
    Tatsumi, T., Takehara, T., Katayama, K., Mochizuki, K., Yamamoto, M., Kanto, T., et al. (1997) Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 25, 1108–1114.CrossRefPubMedGoogle Scholar
  7. 7.
    Collins, F. S., Patrinos, A., Jordan, E., Chakravarti, A., Gesteland, R., and Walters, L. (1998) New goals for the U. S. Human Genome Project: 1998-2003. Science. 282, 682–689.CrossRefPubMedGoogle Scholar
  8. 8.
    Moro, M., Gasparri, A. M., Pagano, S., Bellone, M., Tornaghi, P., Veglia, F., et al. (1999) Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Cancer Res. 59, 2650–2656.PubMedGoogle Scholar
  9. 9.
    Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., et al. (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145–1155.CrossRefPubMedGoogle Scholar
  10. 10.
    Bluestone, J. A. (1996) Costimulation and its role in organ transplantation. Clin. Transplant. 10(Pt. 2), 104–109.PubMedGoogle Scholar
  11. 11.
    Curtsinger, J., Deeths, M. J., Pease, P., and Mescher, M. F. (1997) Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J. Immunol. Methods 209, 47–57.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Andrei I. Chapoval
    • 1
  • Gefeng Zhu
    • 1
  • Lieping Chen
    • 1
  1. 1.Department of ImmunologyMayo Medical School, Mayo ClinicRochester

Personalised recommendations